Washington, United States
Modavar Pharmaceuticals is the US subsidiary of Cadila Pharmaceutical Group, one of the largest privately held pharmaceutical companies globally. With a presence in 7 countries, including the United States, Cadila focuses on developing and manufacturing affordable medicines for patients worldwide. The company's CGMP compliant manufacturing services for prescription pharmaceuticals, along with its state-of-the-art facilities that are approved by USFDA, WHO Geneva, UK MHRA, TGA Australia, MCC South Africa, and ANVISA Brazil, highlight its commitment to quality and compliance.
Founded in 2005, Cadila's innovation-led drug discovery processes prioritize the health and well-being of people globally. The company's enhanced investment in innovation, coupled with its strong track record in research and development (R&D), has significantly impacted patient lives. As a care-focused, research-driven entity, Cadila remains dedicated to maintaining the highest ethical standards in clinical research.
Cadila’s mission to reimagine medicines that enhance and extend the lives of patients underscores its core values. With its focus on biotechnology, healthcare, manufacturing, and pharmaceutical industries, Modavar Pharmaceuticals, representing Cadila in the United States, stands at the forefront of bringing innovative and affordable healthcare solutions to the market.
